 CAMBRIDGE, Mass., Dec. 12, 2022 GLOBE NEWSWIRE -- Magenta Therapeutics Nasdaq: MGTA, a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplant to more patients, today announced that it will host a conference call and webcast at 8:30 a.m. Eastern Time ET 7:30 a.m. Central Time CT tomorrow, Tuesday, December 13, 2022 to review the MGTA-117 clinical data from its ongoing Phase 12 does escalation clinical trial that will be presented at the 2022 American Society of Hematology ASH Annual Meeting. 